27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Nektar Therapeutics Inc (NASDAQ:NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC:MKGAF) and Pfizer Inc (NYSE:PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study.
- The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients.
- NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid tumors.
- Avelumab is marketed in the U.S. as Bavencio, is co-developed and co-commercialized by Merck KGaA and Pfizer.
- The study will begin enrolling patients in Q1 of 2022.
- Price Action: NKTR shares are up 4.53% at $17.08 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!